Difference between revisions of "Gatifloxacin"
(→Adverse Reactions) |
ClaireLewis (talk | contribs) |
||
| (9 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
| − | *Type: | + | *Type: [[Fluoroquinolone]] |
| − | *Dosage Forms: | + | *Dosage Forms: Ophthalmic solution |
*Common Trade Names: Zymar, Zymaxid | *Common Trade Names: Zymar, Zymaxid | ||
==Adult Dosing== | ==Adult Dosing== | ||
| − | * 0.5% solution, 1 gtt in eye q2h up to 8x/day first day, then bid- | + | *0.3% solution, 1 gtt in eye q2h up to 8x/day day 1 and 2, then QID x 5 days |
| + | *0.5% solution, 1 gtt in eye q2h up to 8x/day first day, then bid-QID x 6 days | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| − | *> 1 y/o | + | *> 1 y/o |
| + | **0.3% solution, 1 gtt in eye q2h up to 8x/day day 1 and 2, then QID x 5 days | ||
| + | **0.5% solution, 1 gtt in eye q2h up to 8x/day first day, then bid-QID x 6 days | ||
==Special Populations== | ==Special Populations== | ||
| Line 42: | Line 45: | ||
==Pharmacology== | ==Pharmacology== | ||
| − | *Half-life: | + | *Half-life: N/A (7-14 hours for systemic preparations) |
| − | *Metabolism: | + | *Metabolism: Minimal |
| − | *Excretion: | + | *Excretion: N/A (urine for systemic preparations) |
| − | *Mechanism of Action: | + | *Mechanism of Action: Bactericidal, inhibits DNA gyrase and topoisomerase IV |
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ||
| Line 168: | Line 171: | ||
===Key=== | ===Key=== | ||
{{Template:Antibacterial Spectra Key}} | {{Template:Antibacterial Spectra Key}} | ||
| + | |||
==See Also== | ==See Also== | ||
| − | == | + | ==References== |
| − | |||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Pharmacology]] |
| + | [[Category:ID]] | ||
Latest revision as of 20:08, 22 September 2019
Contents
General
- Type: Fluoroquinolone
- Dosage Forms: Ophthalmic solution
- Common Trade Names: Zymar, Zymaxid
Adult Dosing
- 0.3% solution, 1 gtt in eye q2h up to 8x/day day 1 and 2, then QID x 5 days
- 0.5% solution, 1 gtt in eye q2h up to 8x/day first day, then bid-QID x 6 days
Pediatric Dosing
- > 1 y/o
- 0.3% solution, 1 gtt in eye q2h up to 8x/day day 1 and 2, then QID x 5 days
- 0.5% solution, 1 gtt in eye q2h up to 8x/day first day, then bid-QID x 6 days
Special Populations
- Pregnancy Rating: C
- Lactation: Safety Unknown
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Conjunctival hemorrhage
- Superinfection
Hypersensitivity reaction
Common
- Conjunctival irritation
- Ocular irritation
- Dysgeusia
- Ocular pain
- Chemosis
- Dry eyes
- Ocular discharge
- Blepharitis
- Headache
- Visual acuity changes
Pharmacology
- Half-life: N/A (7-14 hours for systemic preparations)
- Metabolism: Minimal
- Excretion: N/A (urine for systemic preparations)
- Mechanism of Action: Bactericidal, inhibits DNA gyrase and topoisomerase IV
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014